Daniel Louis Hertz

57PUBLICATIONS
136CO-AUTHORS
Predictive and prognostic markersPharmacogenomicsHaematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (57)

|Apr 30, 2026
Lipidomic Predictors of Paclitaxel-Induced Peripheral Neuropathy.

|Apr 28, 2026
Importance of and Strategies for Implementing DPYD Testing to Prevent Severe Fluoropyrimidine Chemotherapy Toxicity in Health Care Systems.

|Feb 27, 2026
Identification of Additional DPYD Polymorphisms That Increase the Risk of Severe Fluoropyrimidine Toxicity and Improve Predictive Accuracy when Combined with Previously Validated Variants.

Nam Nguyen-Hoang, Kelly Nugent, Sophia Jaso

|Feb 03, 2026
Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/DPYD) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing.

Daniel L Hertz, Alan P Venook

|Dec 05, 2025
Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer.

Nadine Norton, Nicholas B Larson, Gregory D Jenkins

|Nov 14, 2025
Pharmacokinetic-Pharmacodynamic Model of Paclitaxel-Induced Peripheral Neuropathy.

Yuchen Sun, Manjunath P Pai, N Lynn Henry

Pageof 10

Frequent Collaborators

10 joint publications

N Lynn Henry

5 joint publications

Amy L Pasternak

5 joint publications

J Kevin Hicks

5 joint publications

Jai N Patel